Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine.

Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Muñoz A, Lagos R, Levine MM, Pasetti MF.

Clin Vaccine Immunol. 2011 Mar;18(3):355-61. doi: 10.1128/CVI.00354-10. Epub 2011 Jan 12.

2.

Topological approach of Jungian psychology.

Viret J.

Acta Biotheor. 2010 Sep;58(2-3):233-45. doi: 10.1007/s10441-010-9106-9. Epub 2010 Jul 24.

PMID:
20658172
3.

New strategies to overcome the drawbacks of currently available flu vaccines.

Fichera E, Felnerova D, Mischler R, Viret JF, Glueck R.

Adv Exp Med Biol. 2009;655:243-52. doi: 10.1007/978-1-4419-1132-2_15. Review.

PMID:
20047044
4.

Editorial: characterization and analysis of heterogeneity in biological systems.

Manté C, Nerini D, Viret J.

Acta Biotheor. 2008 Jun;56(1-2):1-3. doi: 10.1007/s10441-008-9027-z. Epub 2008 Jan 30. No abstract available.

PMID:
18231865
5.
6.

Morphological and immunocytochemical analysis of Escherichia coli-specific surface antigens in wildtype strains and in recombinant Vibrio cholerae.

Lüdi S, Frey J, Favre D, Viret JF, Ziethlow V, Boghenbor KK, Stoffel MH.

Antonie Van Leeuwenhoek. 2008 Jan-Feb;93(1-2):185-92. Epub 2007 Aug 21.

PMID:
17710560
7.

[Surviving the dissolution of marriage: age and patrimony in Ile-de-France in the mid-17th century].

Viret JL.

Hist Econ Soc. 2002;21(2):181-200. French. No abstract available.

PMID:
17387816
8.

A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults.

Simon JK, Pasetti MF, Viret JF, Mischler R, Muñoz A, Lagos R, Levine MM, Campbell JD.

Hum Vaccin. 2007 Mar-Apr;3(2):54-8. Epub 2007 Mar 10.

PMID:
17312403
9.

Attenuated measles virus as a vaccine vector.

Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, Wild P, Viret JF, Glueck R, Billeter MA, Naim HY.

Vaccine. 2007 Apr 20;25(16):2974-83. Epub 2007 Feb 2.

10.

Viral vectors for malaria vaccine development.

Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F.

Vaccine. 2007 Mar 30;25(14):2567-74. Epub 2006 Aug 1. Review.

PMID:
16914237
11.

Generalised biological function.

Viret J.

Acta Biotheor. 2005;53(4):393-409.

PMID:
16583278
12.

Expression of enterotoxigenic Escherichia coli colonization factors in Vibrio cholerae.

Favre D, Lüdi S, Stoffel M, Frey J, Horn MP, Dietrich G, Spreng S, Viret JF.

Vaccine. 2006 May 15;24(20):4354-68. Epub 2006 Mar 20.

PMID:
16581160
13.

Lawrence Bogorad (1921-2003), a pioneer in photosynthesis research: a tribute.

Rodermel S, Viret JF, Krebbers E.

Photosynth Res. 2005;83(1):17-24. No abstract available.

PMID:
16143903
14.

Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation.

Favre D, Viret JF.

Vaccine. 2006 May 1;24(18):3856-64. Epub 2005 Aug 2. Review.

PMID:
16115705
15.

Plasmid maintenance systems suitable for GMO-based bacterial vaccines.

Spreng S, Viret JF.

Vaccine. 2005 Mar 18;23(17-18):2060-5. Review.

PMID:
15755571
16.

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch.

Frech SA, Kenney RT, Spyr CA, Lazar H, Viret JF, Herzog C, Glück R, Glenn GM.

Vaccine. 2005 Jan 4;23(7):946-50.

PMID:
15603897
17.

Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs.

Felnerova D, Viret JF, Glück R, Moser C.

Curr Opin Biotechnol. 2004 Dec;15(6):518-29. Review.

PMID:
15560978
18.

The survival attractor in the sensory functions: the example of hearing.

Sendowski I, Viret J.

Acta Biotheor. 2004;52(4):401-14.

PMID:
15520542
19.

Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.

Lambkin R, Oxford JS, Bossuyt S, Mann A, Metcalfe IC, Herzog C, Viret JF, Glück R.

Vaccine. 2004 Oct 22;22(31-32):4390-6.

PMID:
15474733
20.

Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.

Viret JF, Dietrich G, Favre D.

Vaccine. 2004 Jun 23;22(19):2457-69. Review.

PMID:
15193410
21.

Development of a SARS vaccine: an industrial perspective on the global race against a global disease.

Viret JF, Glück R, Moser C.

Expert Rev Vaccines. 2003 Aug;2(4):465-7. No abstract available.

PMID:
14711331
22.
23.

Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine.

Zurbriggen R, Metcalfe IC, Glück R, Viret JF, Moser C.

Expert Rev Vaccines. 2003 Apr;2(2):295-304. Review.

PMID:
12899579
24.

Virosomal adjuvanted antigen delivery systems.

Moser C, Metcalfe IC, Viret JF.

Expert Rev Vaccines. 2003 Apr;2(2):189-96. Review. Erratum in: Expert Rev Vaccines. 2003 Dec;2(6):842.

PMID:
12899570
25.

Haemolysin A and listeriolysin--two vaccine delivery tools for the induction of cell-mediated immunity.

Dietrich G, Viret JF, Gentschev I.

Int J Parasitol. 2003 May;33(5-6):495-505. Review.

PMID:
12782050
26.

Live attenuated bacteria as vectors to deliver plasmid DNA vaccines.

Dietrich G, Spreng S, Favre D, Viret JF, Guzman CA.

Curr Opin Mol Ther. 2003 Feb;5(1):10-9. Review.

PMID:
12669465
27.

Novel vaccination strategies based on recombinant Mycobacterium bovis BCG.

Dietrich G, Viret JF, Hess J.

Int J Med Microbiol. 2003 Feb;292(7-8):441-51. Review.

PMID:
12635927
28.

Experience with registered mucosal vaccines.

Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret JF.

Vaccine. 2003 Jan 30;21(7-8):678-83. Review.

PMID:
12531339
29.

Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments.

Dietrich G, Viret JF, Hess J.

Vaccine. 2003 Jan 30;21(7-8):667-70. Review.

PMID:
12531337
30.

Sensitivity of HCV RNA and HIV RNA blood screening assays.

Lelie PN, van Drimmelen HA, Cuypers HT, Best SJ, Stramer SL, Hyland C, Allain JP, Moncharmont P, Defer C, Nübling M, Glauser A, da Silva Cardoso M, Viret JF, Lankinen MH, Grillner L, Wirthmüller U, Coste J, Schottstedt V, Masecar B, Dax EM.

Transfusion. 2002 May;42(5):527-36.

PMID:
12084160
31.

Positive-negative selection for homologous recombination in Arabidopsis.

Xiaohui Wang H, Viret JF, Eldridge A, Perera R, Signer ER, Chiurazzi M.

Gene. 2001 Jul 11;272(1-2):249-55.

PMID:
11470531
32.

Hydrodynamic model of heat stroke.

Viret J, Tela L, Canini F, Bourdon L.

Acta Biotheor. 2000 Dec;48(3-4):259-72.

PMID:
11291944
33.

Hydrodynamic modelling of stress.

Viret J, Grimaud L, Jimenez J.

Acta Biotheor. 1999;47(3-4):173-90.

PMID:
10855265
34.

European multi-centre validation study of NucliSens Extractor in combination with HCV Amplicor 2.0 assay for HCV-NAT screening of plasma pools.

Cuypers HT, van Dijk R, Viret JF, Schottstedt V, Lankinen M, Da Silva Cardoso M, Lelie PN.

Biologicals. 1999 Dec;27(4):303-14.

PMID:
10686057
35.

Gene replacement in gram-negative bacteria: the pMAKSAC vectors.

Favre D, Viret JF.

Biotechniques. 2000 Feb;28(2):198-200, 202, 204. No abstract available.

36.
37.
38.

Enhancement of somatic intrachromosomal homologous recombination in Arabidopsis by the HO endonuclease.

Chiurazzi M, Ray A, Viret JF, Perera R, Wang XH, Lloyd AM, Signer ER.

Plant Cell. 1996 Nov;8(11):2057-66.

39.

Versatile cosmid vectors for facilitated analysis and subcloning of the insert.

Favre D, Viret JF.

Gene. 1996 Oct 31;178(1-2):43-9.

PMID:
8921890
40.
41.

Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR.

Favre D, Struck MM, Cryz SJ Jr, Viret JF.

Vaccine. 1996 Apr;14(6):526-31.

PMID:
8782351
42.

Expression of Shigella sonnei lipopolysaccharide in Vibrio cholerae.

Viret JF, Cryz SJ Jr, Favre D.

Mol Microbiol. 1996 Mar;19(5):949-63.

PMID:
8830276
44.

Modifications of erythrocyte membrane fluidity from patients with anorexia nervosa before and after refeeding.

Lejoyeux M, Bouvard MP, Viret J, Daveloose D, Ades J, Dugas M.

Psychiatry Res. 1996 Jan 31;59(3):255-8.

PMID:
8930032
45.

Selective modifications of the phospholipid fatty acid composition in human platelet membranes using nonspecific and specific lipid transfer proteins.

Bayon Y, Croset M, Guerbette F, Daveloose D, Chirouze V, Viret J, Kader JC, Lagarde M.

Anal Biochem. 1995 Sep 1;230(1):75-84.

PMID:
8585633
46.

Activity of the yeast FLP recombinase in Arabidopsis.

Sonti RV, Tissier AF, Wong D, Viret JF, Signer ER.

Plant Mol Biol. 1995 Sep;28(6):1127-32.

PMID:
7548830
47.

Polyclonal preparations of anti-tetanus toxoid antibodies derived from a combinatorial library confer protection.

Lang AB, Vogel M, Viret JF, Stadler BM.

Biotechnology (N Y). 1995 Jul;13(7):683-5.

PMID:
9634805
48.

Optimization of respiratory pattern during exercise.

Benchetrit G, Dinh TP, Viret J.

Adv Exp Med Biol. 1995;393:225-9. No abstract available.

PMID:
8629485
49.

Effect of specific phospholipid molecular species incorporated in human platelet membranes on thromboxane A2/prostaglandin H2 receptors.

Bayon Y, Croset M, Daveloose D, Guerbette F, Chirouze V, Viret J, Kader JC, Lagarde M.

J Lipid Res. 1995 Jan;36(1):47-56.

50.

[NMR study of membrane incorporation of cysteamine].

Laval JD, Debouzy JC, Fauvelle F, Viret J, Fatome M.

Ann Pharm Fr. 1995;53(3):131-4. French.

PMID:
7677394

Supplemental Content

Support Center